ArticleJournal of the Pediatric Infectious Diseases Society2016
Incidence, Morbidity, and Costs of Human Metapneumovirus Infection in Hospitalized Children.
Article in Journal of the Pediatric Infectious Diseases Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Influenza and other respiratory viruses: standardizing disease severity in surveillance and clinical trials.Expert review of anti-infective therapy · 2017Pooled it
- Epidemiology of Human Metapneumovirus Infection-A Systematic Review and Meta-Analysis.Health science reports · 2026Review
- Disease Spectrum of Human Metapneumovirus Infections in Infants and Young Children: Data From a Prospective Multicenter Study in Germany.The Pediatric infectious disease journal · 2026Article
- Burden of laboratory-confirmed RSV hospitalization in children <5 years-of-age; 2019-2022.BMC pediatrics · 2026Article
- Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry.Open forum infectious diseases · 2026Article
- Avian Metapneumovirus: Virology, Epidemiology, and Insights from a Comparative Analysis with Human Metapneumovirus-A Review.Biomolecules · 2026Review
- Article
- Human metapneumovirus prevention in children: emerging roles of monoclonal antibodies and vaccines.Frontiers in immunology · 2026Review
- Human Metapneumovirus (HMPV): A comprehensive review of its virology, epidemiology, clinical features, and advances in diagnosis and prevention.Northern clinics of Istanbul · 2026Review
- Pediatric Antibiotic Use Associated With Respiratory Syncytial Virus and Influenza in the United States, 2008-2018.The Journal of infectious diseases · 2025Article
- Risk Factors for Pediatric Intensive Care Unit Admission in Children with Human Metapneumovirus Infections.Infection & chemotherapy · 2025Article
- Human Metapneumovirus: A Narrative Review on Emerging Strategies for Prevention and Treatment.Viruses · 2025Review
- Epidemiology of Human Metapneumovirus Infection in a Community Setting, Seattle, Washington, USA.The Journal of infectious diseases · 2025Article
- Human Metapneumovirus: A Comprehensive Epidemiological Analysis of a Global Respiratory Threat.Infection & chemotherapy · 2025Review
- Review
- Clinical characterisation of human metapneumovirus infection in 525 patients with respiratory tract infections in Jilin province.Frontiers in cellular and infection microbiology · 2025Article
- Human metapneumovirus: an emerging public health threat and harbinger of a new pandemic.GMS hygiene and infection control · 2025Review
- CIRCULATING VIRAL RESPIRATORY PATHOGENS AS CAUSATIVE AGENT FOR SEVERE ACUTE RESPIRATORY INFECTIONS IN MOROCCO: A SYSTEMATIC REVIEW.African journal of infectious diseases · 2025Article
- Novel insights into the host cell glycan binding profile of human metapneumovirus.Journal of virology · 2024Article
- Ginkgolic acid inhibits orthopneumo- and metapneumo- virus infectivity.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundHuman metapneumovirus (HMPV) causes acute respiratory tract infections in infants and children. We sought to measure the clinical and economic burden of HMPV infection in hospitalized children.
methodsWe conducted a retrospective cohort study from 2007 to 2013 at Primary Children's Hospital in Salt Lake City, Utah. Children <18 years of age with laboratory-confirmed HMPV infection were included. Demographic, clinical, and financial data were abstracted from the electronic medical record.
resultsDuring the study period, 815 children were hospitalized with laboratory-confirmed HMPV infection: 16% <6 months, 50% 6-23 months, 23% 2-4 years, and 11% 5-17 years of age. A complex chronic condition was identified in 453 (56%) children hospitalized with HMPV infection; this proportion increased with increasing age (P < .001). There was marked variation in annual HMPV hospitalization rates, ranging from 9 of 100 000 person-years in 2012-2013 to 79 of 100 000 in 2009-2010. Hospitalization rates were highest among children <2 years (200 of 100 000 person-years) and lowest among children 5-17 years of age (5 of 100 000). Of hospitalized children, 18% were treated in the intensive care unit and 6% required mechanical ventilation. The median length of stay was 2.8 days (interquartile range [IQR], 1.8-4.6) and did not vary by age. The median total hospital cost per patient was $5513 (IQR, $3850-$9946) with significantly higher costs for patients with chronic medical conditions (P < .001).
conclusionsHuman metapneumovirus infection results in a large number of hospitalizations with substantial morbidity, resource utilization, and costs. The development of a safe and effective vaccine could reduce the clinical and economic burden of HMPV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.